Research graph
References from Restoring lysosomal proteostasis reverses steatohepatitis and fibrosis in experimental MASH. Local targets link to admitted publications; unresolved targets remain external evidence.
Lysosomes as hubs of metabolic sensing and cellular homeostasis
10.1016/j.molcel.2026.01.011 · 2026 · External reference
The role of lysosomes in metabolic and autoimmune diseases
10.1038/s41581-023-00692-2 · 2023 · External reference
Autophagy in hepatic adaptation to stress
10.1016/j.jhep.2019.08.026 · 2020 · External reference
Restoration of lysosomal acidification rescues autophagy and metabolic dysfunction in non-alcoholic fatty liver disease
10.1038/s41467-023-38165-6 · 2023 · External reference
Autophagy and hepatic lipid metabolism: mechanistic insight and therapeutic potential for MASLD
10.1038/s44324-024-00022-5 · 2024 · External reference
Involvement of lysosomal dysfunction in autophagosome accumulation and early pathologies in adipose tissue of obese mice
10.1080/15548627.2016.1274850 · 2017 · External reference
Autophagy in liver diseases
10.4254/wjh.v13.i1.6 · 2021 · External reference
Chaperone-mediated autophagy regulates adipocyte differentiation
10.1126/sciadv.abq2733 · 2022 · External reference
Autophagy alterations in obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease: the evidence from human studies
10.1007/s11739-024-03700-w · 2024 · External reference
Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States
10.1016/j.cgh.2020.05.064 · 2021 · External reference
Multi-omics profiling reveals altered mitochondrial metabolism in adipose tissue from patients with metabolic dysfunction-associated steatohepatitis
10.1016/j.ebiom.2024.105532 · 2025 · External reference
Mitochondrial oxidative injury: a key player in nonalcoholic fatty liver disease
10.1152/ajpgi.00121.2020 · 2020 · External reference
Oxidative Stress Is a Key Modulator in the Development of Nonalcoholic Fatty Liver Disease
10.3390/antiox11010091 · 2021 · External reference
The many pathways driving liver inflammation in MASH
2026 · External reference
Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial
10.1136/annrheumdis-2012-202460 · 2013 · External reference
Fluorofenidone attenuates choline-deficient, l-amino acid-defined, high-fat diet-induced metabolic dysfunction-associated steatohepatitis in mice
10.1038/s41598-025-94401-7 · 2025 · External reference
Characterization of six clinical drugs and dietary intervention in the nonobese CDAA-HFD mouse model of MASH and progressive fibrosis
10.1152/ajpgi.00110.2024 · 2025 · External reference
Targeting the endo-lysosomal autophagy pathway to treat inflammatory bowel diseases
10.1016/j.jaut.2022.102814 · 2022 · External reference
The Therapeutic Effect of Phosphopeptide P140 Attenuates Inflammation Induced by Uric Acid Crystals in Gout Arthritis Mouse Model
10.3390/cells11233709 · 2022 · External reference
T cell recognition and therapeutic effect of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MRL/lpr mice
10.1002/immu.200310002 · 2003 · External reference
An Autophagy Modulator Peptide Prevents Lung Function Decrease and Corrects Established Inflammation in Murine Models of Airway Allergy
10.3390/cells10092468 · 2021 · External reference
Serum Lactate Dehydrogenase Is a Novel Predictor for the Severity in the Patients With MAFLD: A Cross-Sectional Study in Hefei, China
10.2147/dmso.s492153 · 2025 · External reference
Pharmacological targets at the lysosomal autophagy-NLRP3 inflammasome crossroads
10.1016/j.tips.2023.11.005 · 2024 · External reference
Identification of ATG7 as a protein ATG8ylation substrate
10.1016/j.celrep.2025.116485 · 2025 · External reference
Emerging roles of ATG7 in human health and disease
10.15252/emmm.202114824 · 2021 · External reference
ATG14 targets lipid droplets and acts as an autophagic receptor for syntaxin18-regulated lipid droplet turnover
10.1038/s41467-024-44978-w · 2024 · External reference
ATG14 and STX18: gatekeepers of lipid droplet degradation and the implications for disease modulation
10.1080/15548627.2024.2350739 · 2024 · External reference
Hepatoprotective drug screening identifies daclatasvir, a promising therapeutic candidate for MASLD by targeting PLIN2
10.1016/j.jlr.2025.100835 · 2025 · External reference
Altered hepatic lipid droplet morphology and lipid metabolism in fasted Plin2-null mice
10.1016/j.jlr.2023.100461 · 2023 · External reference
Dual modulation of lipophagy: From molecular mechanisms to therapeutic interventions in cardiovascular health and disease
10.1016/j.phrs.2026.108204 · 2026 · External reference
Degradation of lipid droplet-associated proteins by chaperone-mediated autophagy facilitates lipolysis
10.1038/ncb3166 · 2015 · External reference
Plin2-mediated lipid droplet mobilization accelerates exit from pluripotency by lipidomic remodeling and histone acetylation
10.1038/s41418-022-01018-8 · 2022 · External reference
Advancing targeted protein degradation for metabolic diseases therapy
10.1016/j.phrs.2022.106627 · 2023 · External reference
Acetylation promotes mutant (MUT) TP53-HSPA8 and HSPA8-BAG3 interactions, facilitating MUT TP53 lysosomal degradation preferentially via CASA
10.1080/15548627.2025.2576615 · 2025 · External reference
The ubiquitin–proteasome system: A potential target for the MASLD
10.1016/j.apsb.2025.01.010 · 2025 · External reference
HSPA8/HSC70 chaperone protein: Structure, function, and chemical targeting
10.4161/auto.26448 · 2013 · External reference
Co-Chaperone Bag-1 Plays a Role in the Autophagy-Dependent Cell Survival through Beclin 1 Interaction
10.3390/molecules26040854 · 2021 · External reference
Modulation of deregulated chaperone-mediated autophagy by a phosphopeptide
10.1080/15548627.2015.1017179 · 2015 · External reference
Blocking nuclear export of HSPA8 after heat shock stress severely alters cell survival
2018 · External reference
Structure of a Bag/Hsc70 complex: convergent functional evolution of Hsp70 nucleotide exchange factors
10.1126/science.1057268 · 2001 · External reference
P140 Peptide Leads to Clearance of Autoreactive Lymphocytes and Normalizes Immune Response in Lupus-Prone Mice
10.3389/fimmu.2022.904669 · 2022 · External reference
HSC70 blockade by the therapeutic peptide P140 affects autophagic processes and endogenous MHCII presentation in murine lupus
10.1136/ard.2010.139832 · 2011 · External reference
MED19 Regulates Adipogenesis and Maintenance of White Adipose Tissue Mass by Mediating PPARγ-Dependent Gene Expression
10.1016/j.celrep.2020.108228 · 2020 · External reference
Multiple anti-non-alcoholic steatohepatitis (NASH) efficacies of isopropylidenyl anemosapogenin via farnesoid X receptor activation and TFEB-mediated autophagy
10.1016/j.phymed.2022.154148 · 2022 · External reference
HawkDock version 2: an updated web server to predict and analyze the structures of protein–protein complexes
10.1093/nar/gkaf379 · 2025 · External reference
The Mediator Complex: A Regulatory Hub for Transcriptional Activity of Nuclear Receptors
10.3390/cells14171335 · 2025 · External reference
Metabolic Dysfunction–Associated Steatotic Liver Disease
10.1056/nejmra2412865 · 2025 · External reference
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
10.1056/nejmoa2309000 · 2024 · External reference
NASH field celebrates ‘hurrah moment’ with a first FDA drug approval for the liver disease
2024 · External reference
Resmetirom for treatment of MASH
10.1016/j.cell.2024.05.009 · 2024 · External reference
Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis
10.1038/s41598-024-70242-8 · 2024 · External reference
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
10.1038/s41573-024-01084-2 · 2025 · External reference
An autophagy-targeting peptide to treat chronic inflammatory demyelinating polyneuropathies
10.1016/j.jaut.2018.05.009 · 2018 · External reference
Therapeutic effects of peptide P140 in a mouse periodontitis model
10.1007/s00018-022-04537-2 · 2022 · External reference
Lysosomes as a therapeutic target
10.1038/s41573-019-0036-1 · 2019 · External reference
Characterization of six clinical drugs and dietary intervention in the nonobese CDAA-HFD mouse model of MASH and progressive fibrosis
10.1152/ajpgi.00110.2024 · 2025 · External reference
Targeting microbiota-generated acetaldehyde to prevent progression of metabolic dysfunction-associated steatotic liver disease
2026 · External reference
Mitochondrial and lysosomal signaling orchestrates heterogeneous metabolic states of regulatory T cells
10.1126/sciimmunol.ads9456 · 2025 · External reference
